Fig. 3
Transcutaneous oxygen saturation of the affected limb improved in auto-BM-MNC and allo-WJ-MSC-treated diabetic patients with CTLI. TcPO2 improved in the auto-BM-MNC and allo-WJ-MSC groups from the first month, which persisted until 12 months after cell-based therapy, unlike the placebo group, whose participants decreased their TcPO2. Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (p < 0.05); placebo group versus allo-WJ-MSC group (*) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group one month post-treatment (ϖ) (p < 0.05); placebo group pre-treatment versus placebo group three months post-treatment (θ) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group three months post-treatment (λ) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group three months post-treatment (ε) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group six months post-treatment (@) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group six months post-treatment (φ) (p < 0.05); auto-BM-MNC group pre-treatment versus auto-BM-MNC group twelve months post-treatment (Λ) (p < 0.05) and allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group twelve months post-treatment (Ω) (p < 0.05). Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cells